TYPES OF INSPECTIONS Comprehensive Abbreviated Preapproval (PAI)

Slides:



Advertisements
Similar presentations
Compliance Monitoring Strategy CMS Michael Pjetraj RCO.
Advertisements

PSM National Emphasis Program for Chemical Facilities(NEP) Columbia Colstor, Inc.
FDA’s Proposed Rule under FSMA for Preventive Controls
Counterfeit Medicines and Fight against Counterfeit Medicines.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
IAEA International Atomic Energy Agency. IAEA Outline Learning objectives Introduction Functions of Regulatory Body (RB) on EPR Appraisal guidance: Part.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Self Audits. The Audit Process Audits are done Biannually (Feb. and Aug.). Audits are done Biannually (Feb. and Aug.). They are performed by persons as.
Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
Current Good Manufacturing Practice: Vaccines
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Understanding cGMPs: What Attorneys Need to Know The Nuts & Bolts of cGMPs Statutory Overview and Basic Concepts James R. Johnson Hogan Lovells US LLP.
Good Laboratory Practices (GLPs)
Regulatory Overview.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
Response to FDA Audit 483 MX-4501N : Nine Category 483 Citations Meetings Minutes: Votes for, against, abstention and reason not recorded;
Understanding cGMPS – What Attorneys Need to Know The Nuts + Bolts of cGMPS July 10, CFR Parts 210 and 211 cGMP case law Andrew D. Bos Senior Director.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Top 10 Medical Device Citations
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Feldman 20 February Pilot Plant through Scale-Up Manufacturing Martha A. Feldman, RAC Drug & Device Development Co., Inc. P.O. Box 3515 Redmond,
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
The Science of Quality By Design Janet Woodcock, M.D. May 19, 2004.
FDA Focus On Consumer Protection
Regulatory Big Brother of Biotechnology. Role of FDA FDA was designed to promote and protect the public’s health Food and Drug Cosmetic Act first passed.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Important informations
Animal Research at Princeton Prepared by Stuart Leland Director, Research Integrity and Assurance For use and distribution by the Princeton University.
Pipelines. Fragile Infrastructure
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
ISLET TRANSPLANTATION: FOCUS ON MANUFACTURING
QSR and GLP What exactly are these?.
ERM and the Pharmaceutical Industry. Risk  An innate part of every aspect of life, and the business environment is of no exception  Severity, both in.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
FDA’s Role in Plant Design Reviews
 ARRANGEMENT OF REGULATIONS  PART I- PRELIMINARY 1. Citation 2. Interpretation 3. Application.
Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.
Experiences (and frustrations) in Developing a Biotech Company in Idaho.
FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.
The Purpose Of A Foodservice Inspection Program Evaluation Protection Education Compliance.
COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.
FDA Facility Evaluation Douglas Stearn Deputy Director for Policy and Analysis Office of Compliance Center for Drug Evaluation and Research.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Clinical Trials.

Pre-Approval-Inspection
FDA Inspections Stephen Joseph Joy’s Quality Management Systems
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Pharmaceutical Quality in the 21st Century
Introduction to Direct-to-Consumer Genetic Testing
Introduction to Quality Risk Management in GCP
Quality System.
Good Manufacturing Practices GMP ممارسات التصنيع الجيد
Prescription for Pharmaceutical Reform: Healing an Ailing System
PAI Readiness For Seven ANDA Products
Federal Food, Drug, and Cosmetic Act 1938, 1954, 1958
Advances in Immunotherapy for Peanut Allergy
How to Respond to a Corporate Warning Letter John M Taylor
Determination of Significant Subcontractor listing on QMS certificates
Compounded Drugs and Lack of Premarket FDA-Approval
Presentation transcript:

TYPES OF INSPECTIONS Comprehensive Abbreviated Preapproval (PAI) Covers all aspects of FDA regulated processes and products. Includes coverage of major areas of the company’s quality systems such as QSR or cGMPs Abbreviated Covers a specific area or explores a greater depth for a particular area. . Includes coverage of one product or specific company operations or a subsystem of QSR or cGMP Preapproval (PAI) Covers preapproval processes for a product; two major components of a PAI. Rigorous, scientific review of safety and efficacy data to support product approval and compliance evaluation of facilities Directed Usually a response to product failure or contamination Includes coverage of conditions that led to this violation

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.